Find Clinical Drug Pipeline Developments & Deals for AB928

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zimberelimab,AB928,AB154

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $1,600.0 million Upfront Cash: $175.0 Million

            Deal Type: Partnership May 27, 2020

            Details:

            Under this agreement, Gilead Gains Broad Access to Arcus’s Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways. Arcus to continue to independently conduct research on New Targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zimberelimab,AB928,AB154

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Taiho Pharmaceutical

            Deal Size: $275.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 26, 2020

            Details:

            Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios.